ArticleMicrobiology spectrum2022
Real-Life Use of Ceftolozane/Tazobactam for the Treatment of Bloodstream Infection Due to Pseudomonas aeruginosa in Neutropenic Hematologic Patients: a Matched Control Study (ZENITH Study).
2 registry-linked trialsOpen access · goldAbstract readMulticenter Study
In one paragraph
Article in Microbiology spectrum, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 24 papers.
0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
2.0field-weighted citation impact, top 12% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Ceftolozane/Tazobactam Versus Meropenem for Febrile Neutropenia on Patients Colonized With or at Risk for Infection With Extended Spectrum Beta Lactamase (ESBL)-Producing Pathogens: a Randomized Double-blind Non-inferiority Trial.
Ceftolozane/Tazobactam vs. Piperacillin/Tazobactam for the Treatment of Bacteremia Due to Enterobacteriaceae and Pseudomonas Aeruginosa in Hemato-oncological Patients With Severe Neutropenia and Fever: Non-inferiority Study
Who cites it
24 citing papers in PubMed, 29 citations in OpenAlex.
- Epidemiology, treatment and outcomes of antimicrobial-resistant infections in hematopoietic stem cell transplant recipients.Current opinion in infectious diseases · 2026Review
- Practice guideline on the prevention and treatment of central line-associated bloodstream infection: Part 2 - Treatment.Journal of intensive medicine · 2026Article
- Clinical Outcomes and Healthcare Resource Utilization of Ceftolozane/Tazobactam in Vulnerable Patient Populations.Antibiotics (Basel, Switzerland) · 2026Article
- Newer antibiotics for drug-resistant Gram-negative infections in immunocompromised hosts: from pivotal trials to high-risk practice.Frontiers in cellular and infection microbiology · 2026Review
- Current and future options for the treatment of serious infections due to carbapenem-resistantClinical microbiology reviews · 2025Review
- Therapeutic management of health care-associated pneumonia.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2025Review
- Can We Lower the Burden of Antimicrobial Resistance (AMR) in Heavily Immunocompromised Patients? A Narrative Review and Call to Action.Infectious diseases and therapy · 2025Review
- Multidrug-resistant Pseudomonas aeruginosa in immunocompromised cancer patients: epidemiology, antimicrobial resistance, and virulence factors.BMC infectious diseases · 2025Article
- Clinical efficacy, safety and pharmacokinetics of novel β-lactam/β-lactamase inhibitor combinations: a systematic review.JAC-antimicrobial resistance · 2025Review
- Towards a holistic approach to pulmonary infections. Insights from the Sixth Annual Meeting of Spanish Experts 2024.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2025Review
- Molecular epidemiology and antimicrobial resistance profiles ofFrontiers in microbiology · 2025Article
- [Clinical features and prognosis of Pseudomonas aeruginosa infection in patients with hematologic malignancies].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2024Article
- Epidemiology of Bacteremia in Patients with Hematological Malignancies and Hematopoietic Stem Cell Transplantation and the Impact of Antibiotic Resistance on Mortality: Data from a Multicenter Study in Argentina.Pathogens (Basel, Switzerland) · 2024Observational
- Systematic Review of Beta-Lactam vs. Beta-Lactam plus Aminoglycoside Combination Therapy in Neutropenic Cancer Patients.Cancers · 2024Review
- Article
- Resistance inAntibiotics (Basel, Switzerland) · 2023Review
- Global impact of antibacterial resistance in patients with hematologic malignancies and hematopoietic cell transplant recipients.Transplant infectious disease : an official journal of the Transplantation Society · 2023Review
- High Rate of Inappropriate Antibiotics in Patients with Hematologic Malignancies and Pseudomonas aeruginosa Bacteremia following International Guideline Recommendations.Microbiology spectrum · 2023Article
- Bloodstream Infection and Gram-Negative Resistance: The Role for Newer Antibiotics.Antibiotics (Basel, Switzerland) · 2023Review
- What to Do with the New Antibiotics?Antibiotics (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
35 authors at 17 institutions in 4 countries.
Alba BergasInfectious Diseases Department, Bellvitge University Hospitalgrid.411129.e, IDIBELL, University of Barcelona, Barcelona, Spain.
Adaia Albasanz-PuigInfectious Diseases Department, Bellvitge University Hospitalgrid.411129.e, IDIBELL, University of Barcelona, Barcelona, Spain.ORCID 0000-0001-9852-5574
Ana Fernández-CruzClinical Microbiology and Infectious Diseases Department, General University Hospital Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain.
Marina MachadoClinical Microbiology and Infectious Diseases Department, General University Hospital Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain.
Andrés NovoHematology Department, Son Espases Hospital, Mallorca, Spain.
David van DuinDivision of Infectious Diseases, University of North Carolina, Chapel Hill, North Carolina, USA.ORCID 0000-0003-4784-3227
Carolina Garcia-VidalInfectious Diseases Department, Hospital Clínic, Barcelona, Spain.
Morgan HakkiDivision of Infectious Diseases, Oregon Health and Science University, Portland, Oregon, USA.
Isabel Ruiz-CampsInfectious Diseases Department, Vall d'Hebron University Hospital, Barcelona, Spain.
José Luis Del PozoInfectious Diseases Division, Clinical Microbiology, Clínica Universidad de Navarra, Immune and Infectious Inflammatory Diseases Research, IdiSNA, Pamplona, Spain.
Chiara OltoliniUnit of Infectious and Tropical Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Catherine DeVoeInfectious Diseases Division, Department of Medicine, University of California, San Franciscogrid.266102.1, California, USA.
Lubos DrgonaOncohematology Department, Comenius University and National Cancer Institute, Bratislava, Slovakia.
Oriol GaschInfectious Diseases Department, Parc Taulí University Hospital, Sabadell, Spain.
Malgorzata MikulskaDivision of Infectious Diseases, University of Genova and San Martino Hospital, Genoa, Italy.
Pilar Martín-DávilaInfectious Diseases Department, Ramon y Cajal Hospital, Madrid, Spain.
Maddalena PeghinInfectious Diseases Clinic, Department of Medicine, University of Udine and Azienda Sanitaria Universitaria Integrata, Udine, Italy.ORCID 0000-0002-4640-679X
Lourdes VázquezHematology Service, Hospital Clínico Universitario, Salamanca, Spain.
Júlia Laporte-AmargósInfectious Diseases Department, Bellvitge University Hospitalgrid.411129.e, IDIBELL, University of Barcelona, Barcelona, Spain.
Xavier Durà-MirallesInfectious Diseases Department, Bellvitge University Hospitalgrid.411129.e, IDIBELL, University of Barcelona, Barcelona, Spain.
Natàlia PallarèsStatistics Advisory Service, Institute of Biomedical Research of Bellvitge, Barcelona, Spain.
Eva González-BarcaHematology Department, Institut Català d'Oncologia (ICO), Hospital Duran i Reynals, IDIBELL, University of Barcelona, Barcelona, Spain.
Ana Álvarez-UríaClinical Microbiology and Infectious Diseases Department, General University Hospital Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain.
Pedro Puerta-AlcaldeInfectious Diseases Department, Hospital Clínic, Barcelona, Spain.
Juan Aguilar-CompanyInfectious Diseases Department, Vall d'Hebron University Hospital, Barcelona, Spain.
Francisco Carmona-TorreInfectious Diseases Division, Clinical Microbiology, Clínica Universidad de Navarra, Immune and Infectious Inflammatory Diseases Research, IdiSNA, Pamplona, Spain.
Teresa Daniela ClericiHematology Department, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Sarah B DoernbergInfectious Diseases Division, Department of Medicine, University of California, San Franciscogrid.266102.1, California, USA.
Lucía PetrikovaOncohematology Department, Comenius University and National Cancer Institute, Bratislava, Slovakia.
Silvia CapillaMicrobiology Department, Parc Taulí University Hospital, Sabadell, Spain.
Laura MagnascoDivision of Infectious Diseases, University of Genova and San Martino Hospital, Genoa, Italy.
Jesús FortúnInfectious Diseases Department, Ramon y Cajal Hospital, Madrid, Spain.
Nadia CastaldoInfectious Diseases Clinic, Department of Medicine, University of Udine and Azienda Sanitaria Universitaria Integrata, Udine, Italy.
Jordi CarratalàInfectious Diseases Department, Bellvitge University Hospitalgrid.411129.e, IDIBELL, University of Barcelona, Barcelona, Spain.
Carlota GudiolInfectious Diseases Department, Bellvitge University Hospitalgrid.411129.e, IDIBELL, University of Barcelona, Barcelona, Spain.ORCID 0000-0003-3095-4422
Bellvitge University Hospital · ESHospital General Universitario Gregorio Marañón · ESOspedale Policlinico San Martino · ITUniversity of Udine · ITVita-Salute San Raffaele University · ITDeleted InstitutionHospital Clínic de Barcelona · ESInstituto de Salud Carlos III · ESUniversity of California, San Francisco · USVall d'Hebron Hospital Universitari · ESClinica Universidad de Navarra · ESComenius University Bratislava · SKHospital Clínico Universitario de Valencia · ESHospital Universitario Son Espases · ESInstitut d'Investigació Biomédica de Bellvitge · ESOregon Health & Science University · USUniversity of North Carolina at Chapel Hill · US
Funding
No grant is acknowledged in the PubMed record.
Abstract
We sought to assess the characteristics and outcomes of neutropenic hematologic patients with Pseudomonas aeruginosa (PA) bloodstream infection (BSI) treated with ceftolozane-tazobactam (C/T). We conducted a multicenter, international, matched-cohort study of PA BSI episodes in neutropenic hematologic patients who received C/T. Controls were patients with PA BSI treated with other antibiotics. Risk factors for overall 7-day and 30-day case fatality rates were analyzed. We compared 44 cases with 88 controls. Overall, 91% of episodes were caused by multidrug-resistant (MDR) strains. An endogenous source was the most frequent BSI origin (35.6%), followed by pneumonia (25.8%). There were no significant differences in patient characteristics between groups. C/T was given empirically in 11 patients and as definitive therapy in 41 patients. Treatment with C/T was associated with less need for mechanical ventilation (13.6% versus 33.3%;
Indexed as
NeutropeniaPneumoniaPseudomonas InfectionsSepsisAnti-Bacterial AgentsCephalosporinsCohort StudiesDrug Resistance, Multiple, BacterialHumansMicrobial Sensitivity TestsPseudomonas aeruginosaTazobactamAnti-Bacterial AgentsceftolozaneCephalosporinsTazobactambacteremiabloodstream infectionceftolozane/tazobactamhematologic malignancymultidrug-resistantneutropeniaPseudomonas aeruginosa
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
NCT06342115ClinicalTrials.gov
NCT06422533ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.